From Evidence To AI: Why The Future Of Oncology Decision Support Must Be Built On Living Evidence
This article was originally published in Forbes on 18 September 2025. How do oncologists decide which treatment to give their patients? It’s rarely an easy choice. Physicians must weigh multiple levels of information, such as the patient’s disease stage, genetic markers, previous therapies, overall health in general and even personal preferences. Then comes the quest for evidence. In order to validate the optimal way forward, oncologists need not only know what is effective, but also whether it is FDA-approved, guideline-adherent or available through a clinical trial. To find the best, most up-to-date information, that validation typically involves toggling between PubMed, society guidelines, journal notifications and conference summaries, and then rationalizing information that doesn’t always align. All of this is tedious and time-consuming. Time that most oncologists don’t have. In a high-volume clinic, a medical oncologist may see 30 to 50 patients in a day. But even with all of those time pressures, each and every decision should be made with the latest, most complete and scientifically valid evidence available. The stakes are high. With the mountain of new research and evidence published in oncology journals constantly expanding, evidence literally shifts by the day. Those shifts in evidence—the decisions between the right and wrong treatment—can be life or death. The Enduring Value Of Evidence Hierarchies Medicine has long recognized that not all evidence is created equal. A single case report may stimulate ideas, but it cannot guide practice. Observational studies provide associations but not certainty. Randomized controlled trials minimize bias and provide more insight. But at the very top of the hierarchy are systematic reviews and meta-analyses, which combine the entire weight of the evidence. This hierarchy matters because medicine is complicated. If we relied on anecdotes or headlines in isolation, patients would be subjected to treatments that look promising by themselves but prove ineffective or even counterproductive when considered in context. For this reason, organizations from the FDA to WHO mandate Systematic Literature Reviews (SLRs) when shaping guidelines, approvals and policies. Systematic reviews are the gold standard for evaluating medical evidence—the safety net for modern medicine. They prevent us from the risks of cherry-picking studies, overvaluing anecdotes or relying on unverified opinions. The Lure And Risk Of Chatbots Given the deluge of new medical information—and the tedium of just reading it all, let alone evaluating it—it’s no wonder that AI chatbots have captured attention. Faced with information overload, the idea of typing a quick question and receiving a fluent, confident paragraph or two is more than just appealing. It can be viewed as a lifeline for busy oncologists. But that’s where the danger lies. Chatbots don’t conduct systematic reviews. They can’t distinguish between high-quality trials and weak studies. They don’t verify whether a therapy is FDA-approved or buried in an outdated guideline. And in some cases, they even fabricate references, miss key data or rank that data inappropriately. Convenience can be seductive, but in oncology, where the margin for error is minute, the cost of error, or incomplete or inaccurate information, is disastrous. That convenience might be harmless if you’re asking Siri to find the nearest grocery store. But in cancer treatment, the right choice can extend life. The wrong choice can cut it short. Evidence Hierarchies Matter Everywhere The lesson extends well beyond oncology. In cardiology, guidelines for heart failure shift frequently. Missing an update could mean prescribing a less effective therapy. In infectious disease, choosing the wrong antibiotic fuels global resistance—making “tried and true” therapies less potent, and new approved therapies a better solution. Outside of medicine, the same principle holds true. Financial advisors trust portfolio strategies grounded in decades of cumulative analysis, not a single trader’s hunch. Aviation safety regulations are shaped by the aggregation of countless investigations, not anecdotal exceptions. Across industries, systematic, comprehensive evidence beats selective inputs every time. From Static Reviews To Living Evidence If chatbots aren’t the solution, then what is? The answer lies in bringing evidence hierarchies into the era of AI. Imagine a living systematic review in real-time, providing a comprehensive, up-to-date synthesis of the evidence—backed by AI and vetted by humans. Instead of replacing systematic reviews, AI in this new paradigm augments them. Algorithms filter through the sheer volume of new publications, screen for relevance, raise quality issues and update evidence maps in real time. And then experts evaluate the results before they reach the physician’s desktop. This model is rigorous yet addresses medicine’s biggest bottleneck—time. Doctors would no longer be forced to sort through hundreds of studies manually. Instead, they would access a dynamic, physician-ready summary rooted in the totality of evidence. AI does the heavy lifting of scanning and sorting, while human experts remain the arbiters of interpretation. A Human-AI Partnership This combination is the future that I am dedicated to and the foundation of the work that my team is producing. At Oncoscope, we don’t rely on generative AI to spin out answers. Instead, we use a suite of AI models to reproduce and accelerate the standardized steps of a systematic review. Think of it like a symphony. AI can tune the instruments, arrange the sheet music and keep the score updated in real time. But only the conductor—the oncologist—can interpret the music for the audience. This collaboration leverages each party’s strength: Machines are better at speed and repetition, while humans are better at judgment and context. The end product is evidence, both thorough and up-to-date, that doesn’t overwhelm the clinicians who need to implement it. Why Caution Matters Now The enthusiasm around AI in healthcare is understandable. Physicians are busy, patients are better informed than ever and the pace of discovery keeps accelerating. But in our rush to adopt new technology, we risk abandoning the very safeguards that make modern medicine safe. It would be unthinkable to prescribe chemotherapy based on a single press release, yet we risk doing something similar if we accept unverified chatbot outputs at face value. In oncology, where decisions can never be undone, shortcuts are dangerous. Archibald Cochrane, the father
Systematic Literature Review Versus Chatbots: Why In Oncology, It’s Not a Choice
In the age of artificial intelligence, speed is often mistaken for rigor. Nowhere is this more dangerous than in oncology, where treatment decisions can mean the difference between life and death. Some technology companies tout “systematic literature reviews” (SLRs) generated in minutes by chatbots that claim to scan thousands of papers across the internet. The appeal is obvious: quick, accessible, and seemingly comprehensive. But in reality, these outputs are neither systematic nor reliable. For oncologists, payers, and researchers, understanding the distinction between a true SLR and a chatbot’s surface-level search is not just academic—it’s essential. The Gold Standard: What a True SLR Involves Systematic literature review is the gold standard for evidence synthesis in medicine. It is the foundation of evidence-based practice because it minimizes bias, ensures completeness, and enables decisions to rest on the strongest available science. A rigorous SLR begins with a protocol: a predefined roadmap that frames the research question and methods. It requires carefully constructed search strategies, typically using combinations of keywords and controlled vocabulary, to capture every relevant publication across peer-reviewed databases. The process doesn’t stop there. Grey literature—such as abstracts from scientific conferences—must also be included, since cutting-edge oncology data often appears in congress presentations long before it reaches a journal. From there, studies undergo multi-step screening against strict inclusion and exclusion criteria: patient population, interventions, comparators, outcomes, and study design (the classic PICO framework). Each selected paper is then critically appraised for quality and relevance. Only after this painstaking filtering does the work of synthesis and interpretation begin. This is not a clerical exercise. It requires advanced training, sound judgment, and clinical insight to evaluate conflicting results, contextualize findings, and translate them into actionable conclusions. Why Chatbots Fall Short Chatbots, even those powered by large language models (LLMs), cannot replicate this process. At best, they skim unstructured text. At worst, they hallucinate citations or omit critical studies. They lack protocols, inclusion criteria, appraisal of study quality, or a transparent audit trail. What results may look convincing on the surface—but lacks the depth and reliability required in oncology. When a chatbot says it can “review 1,000 studies in seconds,” what it’s really doing is producing a text summary based on whatever sources it happens to ingest. There is no guarantee that the sources are peer-reviewed, complete, current, or even real. That is not an SLR. Why It Matters in Oncology Oncology is not forgiving of shortcuts. Selecting the right therapy for a patient is an exercise in precision: choosing between regimens, sequencing targeted therapies, balancing efficacy and toxicity, and staying current on breakthroughs that can extend survival or improve quality of life. In this context, incomplete, outdated, or fabricated evidence isn’t a minor flaw—it’s a threat to patient safety. The rigor of a systematic literature review is not a “nice to have”; it’s the foundation for making responsible decisions in cancer care. The Path Forward AI absolutely has a role to play in evidence synthesis. When paired with human expertise and transparent methodology, it can accelerate searches, streamline screening, and reduce administrative burden. But AI must serve the process—not replace it. In oncology, the choice isn’t between a chatbot and a systematic literature review. It’s between cutting corners and saving lives. The stakes are too high for anything less than living, rigorous, and human-guided evidence. Anna Forsythe Anna Forsythe is the Founder and President of Oncoscope-AI, the first platform to bring together real-time oncology treatment data, clinical guidelines, research publications, and regulatory approvals — all in one place, just like Expedia for cancer care. Available free to oncology professionals worldwide, Oncoscope-AI is redefining how cancer care information is accessed and applied.
From Cochrane To Chatbots: Why Evidence Matters Now More Than Ever In The AI Era
This article was originally published in Forbes on 02 September 2025. In oncology, discovery is moving at warp speed. Hundreds of new studies are published each week, sometimes more than a dozen in a single day. For patients and providers, this fire hose of information could equate to life-saving breakthroughs—a new biomarker, a novel dosing schedule or a survival-prolonging treatment. But it also equates to risk. Misinterpret a flawed trial, overtrust anecdotal experience or trust the wrong person, and patients are left at the mercy of ineffective or even harmful treatments. And so, as this deluge of data overwhelms us with such velocity, the imperative is ensuring that decisions are well-informed by precise, whole and transparent evidence. That all starts with one man: Archibald Leman Cochrane. Archibald Cochrane: The Original Evidence Disruptor Archibald Cochrane was a British physician and epidemiologist who served as a prisoner-of-war doctor in World War II. With effectively no medicines at his disposal, he watched patients suffer because care was based more on habit than proof. After the war, he became an outspoken advocate for a revolutionary principle: Medicine must be based on evidence that has been tested and proven, not on practice or expert opinion. In 1972, he published Effectiveness and Efficiency: Random Reflections on Health Services, a text that shook the medical establishment through criticism of its reliance on anecdotes. He argued that randomized controlled trials (RCTs) were required to determine whether treatments were effective and called for doctors and patients to be presented with objective summaries of all pertinent evidence. His vision inspired the Cochrane Collaboration, founded in 1993, which remains the global leader in producing systematic reviews. Pre-Cochrane, the concept of a controlled clinical trial did not exist. He was the one who established the use of controlled clinical trials, which have now become the gold standard for evaluating new treatments. Building On Solid Ground Cochrane’s work gave us the pyramid of evidence, often used to illustrate the hierarchy of reliability. The higher you climb in the pyramid, the stronger the foundation for life-and-death decisions. Why Systematic Reviews Save Lives In oncology, where treatment options evolve daily, systematic reviews are essential. A single study, whether positive or negative, rarely tells the full story. Systematic reviews, however, consider the entire body of evidence and account for consistency, quality and nuance. Nearly every modern guideline (from the World Health Organization to the FDA) requires systematic reviews as the foundation of clinical recommendations. These methods are necessary because lives depend on them. When Chatbots Pretend To Be Experts We’ve now entered the AI era, where large language models and chatbots can generate fluent answers to intricate medical questions in seconds. To overwhelmed oncologists confronting a deluge of literature, this might look like salvation. But these tools don’t follow the hierarchy of evidence. They don’t methodically scan all the studies, grade the quality of trials or reveal how they arrived at their conclusions. They generate responses based on text patterns that are sometimes accurate, sometimes incomplete and sometimes entirely fabricated. I’ve heard an example just last week from one of my medical colleagues: An AI tool produced a reference under his name for an article he had never written. It was a perfect illustration of how these systems behave like an overeager student desperate to provide an answer, even if that means inventing one. A chatbot’s “best guess” could mean proposing a treatment that introduces unnecessary toxicity to patients or worse, missing a well-documented new trial that would improve survival. The irony is that most of us would never hand over the task of booking a flight to a chatbot without carefully double-checking everything—the departure point, the destination city, the time of day. Yet somehow, when it comes to medical treatment, many are willing to accept incomplete or outdated chatbot outputs at face value. That disconnect should give us pause. Fluency Isn’t Truth One of the greatest risks of AI in medicine is that it sounds authoritative. Chatbots excel at fluency, but fluency is not the same as truth. At this time, AI simply isn’t ready for the weight we’re placing on it. Too many people are so captivated by what it can do that they forget the most basic principle of science and medicine. You must double-check the information. That fascination is dangerous. It encourages blind trust in answers that may be incomplete, misleading or outright wrong. If we allow fluency to masquerade as reliability, medicine risks sliding backward to the pre-Cochrane era, when anecdotes and authority carried more weight than solid data. Smarter Together I’m not saying that AI has no place in evidence-based medicine. Far from it. Let machines handle the tedious but essential work of scanning thousands of papers, formatting endless references and keeping reviews continuously updated as new trials are published. These are the repetitive housekeeping tasks that often slow researchers down, yet must be done with precision. I often compare it to household chores. AI should be doing the vacuuming so humans can spend their time on meaningful work. That’s exactly how my team approaches it. We’ve built a model that uses 36 different AI systems, integrated under the supervision of PhD-level experts, to make systematic reviews dramatically faster without compromising accuracy. Don’t outsource judgment to machines. Give human experts more bandwidth to do what only they can do: Interpret the evidence, weigh the nuances and make the right decisions for patients. Evidence Still Rules Cochrane warned half a century ago that a great deal of medicine lacked solid evidence. His admonition is even more urgent today. With AI, the danger is overconfidence in fluent machines that sound convincing but aren’t built on rigorous evidence. AI must serve evidence, not replace it. Healthcare leaders, policymakers and clinicians need to insist on transparency, rigor and comprehensiveness as absolute necessities. Because in oncology, and medicine in general, lives are at stake. And regardless of how much the tech advances, one thing will always be true: Evidence still rules. This article is
In the AI Era, Are Doctors Still at the Cutting Edge of Medicine? Oncoscope-AI Founder Anna Forsythe Asks
This article was originally published in Success Magazine. Artificial intelligence (AI) has revolutionized industries, from finance and logistics to advertising and agriculture. It has offered new efficiencies, insights and capabilities that were seemingly unimaginable just a few decades ago. Healthcare is no exception. In oncology, especially, where the volume of emerging research and the complexity of personalized treatments are accelerating, intelligent tools have become integral. Oncoscope-AI, an advanced oncology intelligence platform, was created to respond to this need. The catalyst behind the founding of the company was a profound question: How can AI help doctors keep up with and apply the flood of cancer breakthroughs to improve real-world patient care? The company has made answering that question its mission. Refining the approach to cancer treatment Anna Forsythe, founder of Oncoscope-AI, believes the cancer landscape today is vastly different from what it was 10 years ago. This is particularly evident in breast and lung cancer, two of the most commonly diagnosed cancers worldwide. “Before, a diagnosis of breast cancer meant a standard treatment regimen for nearly all patients. Individual biological differences didn’t matter. But our understanding has evolved,” Forsythe explains. Indeed, what was called “breast cancer” is now understood as multiple subtypes. Each has its own biological behavior, prognosis and treatment response. Similarly, lung cancer has splintered into a web of genetically and immunologically distinct conditions. The era of the one-size-fits-all approach, dominated by blanket chemotherapy, surgery and radiation, is fading. A more refined model of cancer treatment has emerged in its place. Forsythe states that today’s oncology is driven by two approaches. One is immunotherapy, which amplifies the body’s immune response to fight the disease from within. The other is targeted therapy, which focuses on specific biomarkers or genetic mutations within the tumor itself. They’re usually used in tandem with the goal of turning terminal-stage cancers into manageable, chronic conditions. Consider the arrival of CDK4/6 inhibitors palbociclib, ribociclib and abemaciclib and how they changed the landscape for breast cancer treatment. According to research based on trials, CDK4/6 inhibitors are considered revolutionary in breast cancer treatment and have played a key role in slowing progression. Progression-free survival, or how long a patient can live without the cancer worsening, has become the new benchmark of success. New challenges for physicians This progress introduces a new kind of pressure, however. “With every new biomarker discovered, every new targeted therapy or immunotherapy approved, the challenge for physicians multiplies,” Forsythe states. “How can any oncologist stay up to date with thousands of new studies, frequent regulatory updates and a deluge of clinical data?” At a single oncology conference, countless new abstracts may be released in just one cancer type. The expectation is that doctors will somehow process all of this while continuing to see patients, manage treatments and fulfill legal requirements for ongoing medical education. In theory, continuous medical education (CME) should help doctors stay current. In practice, it’s difficult for health professionals to retain all the information. Enter Oncoscope-AI Oncoscope-AI has emerged to empower healthcare professionals. Forsythe, a pharmacist, health economist and former pharmaceutical executive, designed it to bridge the divide between cutting-edge research and practical clinical application. The platform scans thousands of oncology publications using proprietary AI, filters them through an evidence-based framework and presents only the most clinically actionable insights. According to Oncoscope-AI, these findings are reviewed and contextualized by a human research team before being published in the system. The impact of Oncoscope-AI is best felt in patient stories. A friend Forsythe met while traveling was diagnosed with metastatic breast cancer. She had undergone traditional chemotherapy and surgery that left her physically and emotionally drained. “She was then prescribed one of the breakthrough CDK4/6 inhibitors. Her life changed. She regained energy, joy, and time,” Forsythe shares. However, when her cancer began to progress again, her oncologist defaulted to standard chemotherapy, believing there were no more options. There were. However, the doctor didn’t know. Forsythe sent her friend research summaries and articles through Oncoscope-AI, which she later shared with her doctor. She was then prescribed a new-generation therapy. “She’s thriving now,” says Forsythe. “She just returned from a trip to France and is booking another.” Aiming to help health professionals and patients thrive This story raises a question. How many more patients are out there who could live longer, better lives if only their doctors had access to the right information at the right time? “The problem is not the doctors. It’s the data overload,” Forsythe emphasizes. “The solution isn’t replacing physicians with AI, but equipping them with AI tools that distill noise into knowledge and confusion into clarity.” Oncoscope-AI is striving to do just that. It’s working to help oncologists across the globe turn the latest science into tangible outcomes for patients in the exam room, not months later when guidelines catch up. This article is for informational purposes only and does not substitute for professional medical advice. If you are seeking medical advice, diagnosis or treatment, please consult a medical professional or healthcare provider.
New Features Now Live in v1.2!
Oncoscope continues to improve and evolve. Our latest update makes finding the clinical evidence you need – even if you aren’t sure what that is yet – even faster and easier.
The Effective Statistician Podcast: Daily Updated Systematic Literature Reviews – The Future of Oncology
Oncoscope-AI Founder & CEO Anna Forsythe was recently invited to be a guest on Dr. Alexander Schacht‘s “The Effective Statistician” podcast. Listen to the full episode on your podcast platform of choice! Spotify: Pocket Casts: Here’s what Dr. Schacht had to say: How can oncologists and healthcare professionals keep up with the ever-growing body of research to make the best decisions for patients? In this episode, I speak with Anna Forsythe, a pharmacologist, health economist, and founder of Oncoscope-AI, a groundbreaking platform delivering daily updated systematic literature reviews (SLRs) in oncology. Drawing on decades of experience in pharma and health economics, Anna shares how automation and AI are transforming the traditionally tedious SLR process—making up-to-date evidence accessible to clinicians in just a few clicks. Why You Should Listen: ✔ Discover how SLRs are evolving through automation and AI ✔ Learn how real-time data can improve cancer treatment decisions ✔ Understand the balance between innovation and clinical responsibility ✔ Hear about a tool that could change the way guidelines and clinical practice align ✔ Be inspired by a founder’s mission to create impact through altruistic innovation
Oncoscope Officially Launches, Ushering in a New Era of Real-Time Oncology Intelligence
Oncoscope officially launches, offering real-time, powered by AI, oncology insights to doctors. Free for verified clinicians, it helps improve cancer treatment decisions in just three clicks. Oncoscope-AI, a revolutionary oncology intelligence platform, has officially launched following a successful beta phase and over a year of strategic development that involved extensive conversations with practicing oncologists. The platform, which delivers real-time, human-curated cancer insights enhanced by artificial intelligence, is now live and available free of charge to verified healthcare professionals worldwide. Founded by Anna Forsythe, a pharmacist, health economist, and seasoned pharmaceutical executive, Oncoscope addresses a critical gap in oncology care. It gives clinicians instant access to the most current treatment data, FDA approvals, and guideline-aligned information, consolidated into one user-friendly platform. “Doctors do not need more data. They need the right information, at the right time, in a format they can use to make better decisions for their patients,” said Forsythe. “Oncoscope provides that clarity. It is a living library of oncology, curated by experts and built to save lives.” Unlike generic AI tools or static databases, Oncoscope uses trained AI to scan thousands of oncology publications and filters them through a rigorous, evidence-based framework. Each entry is cross-referenced with clinical guidelines and regulatory approvals to ensure usability and relevance. All of the results are carefully scrutinized by a team of experienced researchers. Currently, the platform supports breast and lung cancer, with prostate, bladder, colon, and rectal modules rolling out in the coming months. The process is intuitive. Physicians answer three clinical questions—cancer stage, genetic markers, and prior treatments—and receive a personalized, actionable summary. Each recommended article includes survival data, progression insights, treatment efficacy, and toxicity, extracted across 32 key clinical parameters. “The result is something physicians can actually use in the moment,” said Forsythe. “It takes three clicks to go from a patient in the room to the most up-to-date evidence in the field.” Access to Oncoscope is free for verified healthcare professionals, including physicians, nurses, pharmacists, genetic counselors, and physician assistants. Non-verified users, such as those in finance or consulting, can purchase limited access at a monthly rate, restricted to a single cancer type. This structure reflects the company’s commitment to empowering front-line clinicians with better tools—without barriers. Forsythe, who previously founded and sold a successful health economics company serving global pharmaceutical clients, brings a rare combination of clinical, technical, and business expertise to this venture. She sees Oncoscope not only as a tool, but as a mission. “This platform was born from both professional insight and personal urgency,” she said. “Too many patients are still receiving outdated treatments, simply because their doctors do not have time to stay current. I realized I had the knowledge, the team, and the experience to fix that.” With a lean team, strategic vision, and a rapidly growing user base, Oncoscope is poised to become a trusted global resource in cancer treatment.“We are not just a tech company,” said Forsythe. “We are part of the oncology ecosystem. And we are here to help doctors deliver the best care possible.” Beka Vinogradov is the Digital Communications Lead for Oncoscope-AI. She holds a Master’s in Health Administration and has extensive experience and education in business, marketing, and design.
Saving Lives in Real Time: Why Oncology Must Embrace AI, but Carefully
In January, my close friend Susan received devastating news: after six long years of navigating chemotherapy, surgery, radiation, and a targeted therapy that had finally given her back her quality of life, her breast cancer had returned, this time to her liver. She was terrified, not just of the disease, but of what might come next. “I just don’t want to go through chemo again,” she said, fighting back tears. “Is there anything new?” Her oncologist, she said, was excellent. But like so many today, he was overwhelmed. She feared he wouldn’t have time to search for new options that might have emerged in recent months. As a health economist, I’ve spent years sifting through research and data, and I knew that finding up-to-date, reliable information shouldn’t depend on how many hours a doctor can spare after a crushing workload serving patients in the clinic. The mountain of data is overwhelming to even the most dedicated physician trying to keep up. In 2024 alone, over 4,800 papers were published describing breast cancer clinical trials. In the first three months of 2025, another 860 have already appeared. Meanwhile, headlines everywhere tout artificial intelligence (AI) as a revolutionary force in healthcare. But wise physicians and patients alike know the truth: while AI’s potential is enormous, its safe and meaningful application demands careful human oversight, clinical rigor, and a deep understanding of what is at stake. That’s why I turned to a new kind of tool—an AI system specifically designed for medicine, rigorously vetted by human experts, and built not just to gather data, but to curate it, critically evaluate it, and prioritize clinical relevance. Far beyond your average ChatGPT-style chatbot, the tool was a hybrid system: part artificial intelligence, part human expertise. Behind the scenes, it performed a systematic review of the latest literature, flagged high-quality clinical trials, and filtered out unreliable data, creating a curated, searchable database of real, actionable evidence. Within minutes, this hybrid AI-human platform helped me discover a promising new class of drugs—antibody-drug conjugates or ADCs. These therapies target chemotherapy precisely to cancer cells, sparing healthy tissue and potentially reducing side effects. One ADC had just demonstrated outstanding results in a major clinical trial—results so recent they hadn’t yet made it into official treatment guidelines. Susan shared this information with her oncologist. After reviewing the evidence, he agreed. Today, she is on the new therapy—and planning her next vacation. As Dr. Mehran Habibi, a leading breast cancer surgical oncologist in New York, put it to me recently: “AI can’t replace clinical judgment—but it can support it. The only way physicians will trust these tools is if they know the science behind them has been vetted by humans who understand the stakes.” What’s striking isn’t just the speed with which this information was uncovered, but the fact that it could so easily have been missed, he said. “While oncologists are expected to stay on top of a constantly evolving field, the guidelines they depend on, produced by expert committees, are updated infrequently, and, despite the best of intentions, are not immune to biases or conflicts of interest. Additionally, tools like ChatGPT, while popular, can’t be trusted to provide rigorously sourced, clinically relevant information. They’re prone to consider misinformation and half-truths rampant on the internet, and often present content that is incomplete, outdated, or based on opinion rather than evidence.” ChatGPT and other apps that utilize AI are powerful tools in many fields, but not necessarily for clinical science, which demands the highest rigorous standards to be useful to oncologists, he continued. “We don’t rely on GPS apps that guess which roads exist — we expect accuracy and live updates. We don’t book flights through websites that suggest destinations based on personal blogs instead of real availability. So why would we accept anything less in cancer care?” The future of oncology demands “living guidelines”—dynamic, continuously updated frameworks that reflect the latest discoveries, not just a data-dump collected over the last 12 months. That’s what this new class of AI/human tools can enable. They don’t replace the physician. They equip them. And that’s the real power of this approach: it can free up doctors to spend more time with their patients, not less. AI/human tools can support medical education, help residents prepare for board exams, and enhance shared decision-making by providing clear, visual explanations of treatment paths. Susan’s story has a hopeful turn. But there are countless others who may not be as lucky unless we rethink how we connect patients to the best and latest therapies. The race between cancer and medicine is relentless. It’s time we give our doctors the tools to win it. Not because they make decisions for us, but because they make it easier to find the right ones. Anna Forsythe is the Founder and President of Oncoscope-AI, the first platform to bring together real-time oncology treatment data, clinical guidelines, research publications, and regulatory approvals — all in one place, just like Expedia for cancer care. Available free to oncology professionals worldwide, Oncoscope-AI is redefining how cancer care information is accessed and applied. A clinically trained Doctor of Pharmacy (PharmD), Anna also holds a Master’s in Health Economics and Policy from the University of Birmingham (UK) and an MBA from Columbia University. She previously co-founded Purple Squirrel Economics (acquired by Cytel in 2020) and led Global Value and Access at Eisai Pharmaceuticals, following earlier roles at Novartis and Bayer in clinical research and health economics.